IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus
This study is currently recruiting participants.
Verified June 2017 by Nancy Petry, UConn Health
Sponsor:
UConn Health
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Nancy Petry, UConn Health
ClinicalTrials.gov Identifier:
NCT01760759
First received: August 21, 2012
Last updated: June 23, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In this study, investigators propose to randomize 165 human immunodeficiency virus positive patients to one of three 16-week treatment conditions: (1) standard care; (2) standard care + cell phone-based adherence reminders; or (3) standard care + cell phone-based adherence reminders and contingency management. In this latter condition, patients will earn reinforcement for sending in time- and date-stamped self videos of antiretroviral therapy medication ingestion. Primary outcomes will include viral loads and self-report measures of adherence, and effects will be evaluated both during the treatment period and throughout a one-year follow-up. Investigators hypothesize that the cell phone reminder condition will improve adherence relative to standard care, and the cell phone reminder plus contingency management condition will have the best outcomes. Results from this study may have widespread implications for the use of cell phones as a novel technology to improve initial adherence to antiretroviral therapy, thereby reducing the spread of drug resistant human immunodeficiency virus strains to the community.
| Condition | Intervention |
|---|---|
| HIV | Drug: antiretroviral therapy Behavioral: cell phone reminders Behavioral: contingency management for adherence |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus |
Resource links provided by NLM:
Further study details as provided by Nancy Petry, UConn Health:
Primary Outcome Measures:
- change in copies of human immunodeficiency virus per milliliter [ Time Frame: Week 48 ]
- self-report of medication adherence [ Time Frame: baseline ]
- self-report of medication adherence [ Time Frame: Week 8 ]
- self-report of medication adherence [ Time Frame: Week 16 ]
- self-report of medication adherence [ Time Frame: Week 24 ]
- self-report of medication adherence [ Time Frame: Week 36 ]
- self-report of medication adherence [ Time Frame: Week 48 ]
| Estimated Enrollment: | 165 |
| Actual Study Start Date: | November 2012 |
| Estimated Study Completion Date: | December 2017 |
| Estimated Primary Completion Date: | December 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Usual care
Patients receive antiretroviral therapy.
|
Drug: antiretroviral therapy
Patients receive antiretroviral therapy.
|
|
Experimental: Usual care plus cell phone reminders
Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
|
Drug: antiretroviral therapy
Patients receive antiretroviral therapy.
Behavioral: cell phone reminders
Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
|
|
Experimental: Usual care, reminders & contingency management for adherence
Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
|
Drug: antiretroviral therapy
Patients receive antiretroviral therapy.
Behavioral: cell phone reminders
Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
Behavioral: contingency management for adherence
Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- age > 18 years
- initiating or on an antiretroviral therapy regimen and have a viral load >200 copies/mL in the past 6 months
- one or more risk factors for poor adherence
- English speaking
- willing to use a cell phone to receive reminders and record medication ingestion for up to 16 weeks
- able to read at 5th grade level and pass a brief quiz related to understanding the informed consent form
Exclusion Criteria:
- living in an environment or has a visiting nurse that dispenses antiretroviral therapy medication
- participating in another antiretroviral therapy adherence study
- uncontrolled psychiatric disorders
- significant cognitive impairment
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01760759
Please refer to this study by its ClinicalTrials.gov identifier: NCT01760759
Contacts
| Contact: Ruth Fetter | 860.679.4556 | fetter@uchc.edu | |
| Contact: Wendy Soneson | 860.679.2984 | soneson@uchc.edu |
Locations
| United States, Connecticut | |
| University of Connecticut Health Center | Recruiting |
| Farmington, Connecticut, United States, 06030-3944 | |
| Contact: Ruth Fetter 860-679-4556 fetter@uchc.edu | |
| Principal Investigator: Nancy M Petry, Ph.D. | |
| Nathan Smith Clinic, Yale-New Haven Hospital | Recruiting |
| New Haven, Connecticut, United States, 06520 | |
| Contact: Ruth Fetter 860-679-4556 fetter@uchc.edu | |
| Principal Investigator: Merceditas Villanueva, M.D. | |
| Sub-Investigator: Frederick Altice, M.D. | |
Sponsors and Collaborators
UConn Health
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
| Principal Investigator: | Nancy M Petry, Ph.D. | UConn Health |
More Information
| Responsible Party: | Nancy Petry, Professor, UConn Health |
| ClinicalTrials.gov Identifier: | NCT01760759 History of Changes |
| Other Study ID Numbers: |
12-205O-2 R01HD075630 ( U.S. NIH Grant/Contract ) |
| Study First Received: | August 21, 2012 |
| Last Updated: | June 23, 2017 |
Keywords provided by Nancy Petry, UConn Health:
|
HIV Antiretroviral therapy adherence |
Additional relevant MeSH terms:
|
Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections |
RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on September 21, 2017